Samyang Biopharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Samyang Biopharmaceuticals Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11169
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Samyang Biopharmaceuticals Corp (Samyang Biopharm) researches and develops technology platforms for drug delivery. Its product portfolio comprises transdermal patches, injections, ORC hemostat and others. The company spans its expertise in the development and distribution of biodegradable, synthetic absorbable suture materials, biodegradable dental implant (GTR, GBR) membrane and partially absorbable lightweight Hernia Mesh and single-use absorbable endoscopic loop. Samyang Biopharm also provides active pharmaceutical ingredients (APIs) utilizing novel plant cell culture and semisynthetic technologies. It offers its products for the treatment of breast, lung, ovarian, head and neck cancer, and pneumonia of colitis among others. The company through its subsidiaries collaborates with biotechnology, pharmaceutical, venture firms, research institutes and universities to develop new products and technologies. Samyang Biopharm is headquartered in Gyeonggi-do, South Korea.

Samyang Biopharmaceuticals Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 10
Asset Transactions 10
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 10
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 11
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 12
Samyang Biopharmaceuticals Corp – Key Competitors 13
Samyang Biopharmaceuticals Corp – Key Employees 14
Samyang Biopharmaceuticals Corp – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Product News 16
Jul 27, 2017: Samyang Biopharmaceuticals to take charge in marketing of Transdermals 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts 2
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samyang Biopharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 10
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 11
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 12
Samyang Biopharmaceuticals Corp, Key Competitors 13
Samyang Biopharmaceuticals Corp, Key Employees 14

List of Figures
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Samyang Biopharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • St.George Bank:企業の戦略的SWOT分析
    St.George Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Qualcomm Incorporated (QCOM):企業の財務・戦略的SWOT分析
    Qualcomm Incorporated (QCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Eiffage SA (FGR):電力:M&Aディール及び事業提携情報
    Summary Eiffage SA (Eiffage) is a construction and concession company. It operates in businesses of energy and infrastructure construction, real estate development, road construction, civil engineering, concessions, and public-private partnerships. The company’s activities include construction, reno …
  • Celsion Corp (CLSN)-医療機器分野:企業M&A・提携分析
    Summary Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (L …
  • Loral Space & Communications Inc (LORL):企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Ineos Group AG:企業の戦略的SWOT分析
    Ineos Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Bone Therapeutics SA (BOTHE):企業の財務・戦略的SWOT分析
    Summary Bone Therapeutics SA (Bone Therapeutics) is a cell therapy company that develops autologous and allogeneic cell therapy products. It offers pipeline products such as PREOB, an autologous osteoblastic cell therapy product used for the treatment of osteonecrosis and non-union fractures; and AL …
  • Plant Bioscience Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Plant Bioscience Ltd (PBL) is a technology management company that offers services in plant, food and microbial science. The company provides intellectual property management, patent advisory, licensing and technology transfer services. It offers patient consultation and management services, …
  • IsoRay Inc (ISR):製薬・医療:M&Aディール及び事業提携情報
    Summary IsoRay Inc (IsoRay), formerly Century Park Pictures Corporation, is a medical technology company which develops, manufactures and markets isotope-based personalized brachytherapy products and devices for the treatment of cancer and other malignant tumors. The company produced Cesium-131, a r …
  • Complix NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Complix NV (Complix) is a biopharmaceutical company that discovers and develops alphabodies and pre-clinical programs. The company’s products comprise CMPX-1023, a novel alphabody for autoimmune diseases, and cell penetrating alphabodies for the treatment of cancer, among others. It designs …
  • Acushnet Holdings Corp. (GOLF):企業の財務・戦略的SWOT分析
    Acushnet Holdings Corp. (GOLF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates:企業の戦略・SWOT・財務情報
    Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report Summary Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Marksmen Energy Inc (MAH):企業の財務・戦略的SWOT分析
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd, is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, manages, produces and develops oil and gas properties in Western Canada …
  • Career Education Corporation (CECO):企業の財務・戦略的SWOT分析
    Career Education Corporation (CECO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Davide Campari-Milano S.p.A.:戦略・SWOT・企業財務分析
    Davide Campari-Milano S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Davide Campari-Milano S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Peptimimesis SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Peptimimesis SAS (Peptimimesis) is a biopharmaceutical company that discovers and develops transmembrane therapeutic peptides. The company’s proprietary platform delivers a set of drug candidates that act on strategic targets in the field of immuno-oncology, oncology and immune diseases. Its …
  • Kokubu Group Corp:企業の戦略・SWOT・財務情報
    Kokubu Group Corp - Strategy, SWOT and Corporate Finance Report Summary Kokubu Group Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • CRELUX GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Crelux GmbH (Crelux), a subsidiary of WuXi AppTec (Shanghai) Co Ltd, is a drug discovery company that discovers drug solutions for pharmacy, biotech and research organizations. The company offers customized and integrated services in areas of drug discovery, X-ray crystallography, protein su …
  • SLM Corp:企業の戦略・SWOT・財務情報
    SLM Corp - Strategy, SWOT and Corporate Finance Report Summary SLM Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Pro Petroleum Inc:企業の戦略的SWOT分析
    Pro Petroleum Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆